SIEMENS HEALTHINEERS AG(VARIAN MEDICAL SYSTEMS, INC.)
ELEKTA
ACCURAY INCORPORATED
VIEWRAY TECHNOLOGIES, INC.
C-RAD
IBA
HITACHI LTD.
MEVION MEDICAL SYSTEMS
PANACEA MEDICAL TECHNOLOGIES PVT. LTD.
P-CURE
PROVISION HEALTHCARE
SUMITOMO HEAVY INDUSTRY LTD.
PHILIPS HEALTHCARE
RAYSEARCH LABORATORIES
PROTOM INTERNATIONAL, INC.
OPTIVUS PROTON THERAPY, INC.
TOSHIBA CORPORATION
VISION RT LTD.
ADVANCED ONCOTHERAPY PLC
MIM SOFTWARE INC.
±âŸ ±â¾÷
STANDARD IMAGING, INC.
BRAINLAB AG
MAGNETTX ONCOLOGY SOLUTIONS LTD.
PTW FREIBURG GMBH
DOSISOFT SA
Á¦13Àå ºÎ·Ï
AJY
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
The global robotic radiotherapy market is projected to reach USD 1.9 billion by 2028 from USD 1.1 billion in 2023, growing at a CAGR of 11.9% during the forecast period. The rising prevalence of cancer and the growing use of robotic radiotherapy is one of the major factors anticipated to boost market growth in the forecasting years.
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2023
Forecast Period
2023-2028
Units Considered
Value (USD) Billion
Segments
Product, Technology, Application, End Users, and Region
Regions covered
North America, Europe, Asia Pacific, and the Rest of the world
"3D cameras (SGRT) segment of global robotic radiotherapy market to grow with the highest CAGR in the forecast period."
On the basis of product, the robotic radiotherapy market is segmented into radiotherapy systems, software, 3D cameras, and others. The 3D cameras segment is expected to register the highest CAGR in the forecast period. Growth in this segment is majorly driven by the ability to offer non-invasive, real-time, 6-degree dimensional patient positioning and monitoring before and during the radiation therapy treatment process, resulting in accurate treatment delivery and wide acceptance by cancer facilities. However, factors such as significant maintenance costs associated with SGRT products, as well as the slow implementation of regulatory guidelines for robotic radiotherapy across emerging countries, are expected to restrain market growth.
"Lung cancer segment, by application, accounted for the largest market share of global robotic radiotherapy market in 2020."
Based on application, the global robotic radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head & neck cancer, colorectal cancer, and other cancers. The lung cancer segment accounted for the largest share of the global robotic radiotherapy market in 2022. The major drivers of this segment are increasing smoking rates, exposure to air pollutants, especially in urban areas with poor air quality, and exposure to carcinogens in mining, construction, and manufacturing. Modern lifestyles and dietary habits may further elevate the risk of lung cancer. As the global population ages, lung cancer incidence tends to rise, potentially leading to a higher number of cases.
"Increased installations and government initiatives to drive the segment growth of hospitals end-user segment."
Based on the end user, the robotic radiotherapy market is segmented into hospitals and independent radiotherapy centers. Hospitals are the major end users of robotic radiotherapy products. The large share of this end-user segment is primarily attributed to the demand for automated radiation therapy systems, advancement in automated radiation therapy systems and the increasing installations of ART stations, and the rising government investments for effective ART and treatment.
"The APAC market, by region, to register highest growth rate in the forecast period."
On the basis of region, the robotic radiotherapy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia-Pacific market is likely witness significant growth owing to increase in disposable income and increase in cancer patient pool. Focus on governments on investment on robotic radiotherapy systems, modernization of industrial and public infrastructures, and rising penetration of cutting-edge radiation therapy in hospitals. However, a dearth of skilled professionals for the operation of advanced instruments, slow implementation of therapy due to budgetary constraints, and pricing pressures faced by prominent product manufacturers are the key factors restraining the growth of the robotic radiotherapy market despite the great opportunities available in the APAC region.
A breakdown of the primary participants referred to for this report is provided below:
By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
By Designation: C-level-10%, Director-level-14%, and Others-76%
By Region: North America-40%, Europe-32%, Asia Pacific-20%, Latin America-5%, MEA- 3%
The prominent players in the robotic radiotherapy market are Siemens Healthcare GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), C-RAD (Sweden), IBA Worldwide (Belgium), Hitachi Ltd. (Japan (US), Mevion Medical Systems (US), Optivus Proton Therapy, Inc. (US) and Panacea Medical Technologies Pvt. Ltd. (India), among others.
Research Coverage
This report studies the robotic radiotherapy market based on product, technology, application, end-user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
Analysis of key drivers (growing demand for non-invasive treatments, technological advancements, rising prevalence of cancer, growing use of automated radiation therapy for cancer treatment), restraints (lack of adequate healthcare, high cost of automated radiation therapy systems, complex nature of technology, dearth of skilled radiologist), opportunities (rising healthcare expenditure across developing countries, growing government and private investments, adoption of radiation therapy), and challenges (risk of radiation exposure, competition from alternative treatment modalities) influencing the growth of robotic radiotherapy market
Market Penetration: Comprehensive information on the product portfolios offered by the top players in the robotic radiotherapy market
Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the robotic radiotherapy market
Market Development: Comprehensive information on lucrative emerging regions
Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the market
Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIES COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.5 MARKET STAKEHOLDERS
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.2 PRIMARY RESEARCH
2.2.2.1 Primary sources
2.2.2.2 Key data from secondary sources
2.2.2.3 Breakdown of primaries
FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
(Business Overview, Products/Services/Solutions Offered, Recent Developments, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats)**
12.1.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.)
TABLE 74 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 31 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
12.1.2 ELEKTA
TABLE 75 ELEKTA: COMPANY OVERVIEW
FIGURE 32 ELEKTA: COMPANY SNAPSHOT (2022)
12.1.3 ACCURAY INCORPORATED
TABLE 76 ACCURAY INCORPORATED: COMPANY OVERVIEW
FIGURE 33 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2022)
12.1.4 VIEWRAY TECHNOLOGIES, INC.
TABLE 77 VIEWRAY TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 34 VIEWRAY TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
12.1.5 C-RAD
TABLE 78 C-RAD: COMPANY OVERVIEW
FIGURE 35 C-RAD: COMPANY SNAPSHOT (2022)
12.1.6 IBA
TABLE 79 IBA: COMPANY OVERVIEW
FIGURE 36 IBA: COMPANY SNAPSHOT (2022)
12.1.7 HITACHI LTD.
TABLE 80 HITACHI LTD.: COMPANY OVERVIEW
FIGURE 37 HITACHI LTD.: COMPANY SNAPSHOT (2021)
12.1.8 MEVION MEDICAL SYSTEMS
TABLE 81 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW
12.1.9 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.
TABLE 82 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
12.1.10 P-CURE
TABLE 83 P-CURE: COMPANY OVERVIEW
12.1.11 PROVISION HEALTHCARE
TABLE 84 PROVISION HEALTHCARE: COMPANY OVERVIEW
12.1.12 SUMITOMO HEAVY INDUSTRY LTD.
TABLE 85 SUMITOMO HEAVY INDUSTRY LTD.: COMPANY OVERVIEW
FIGURE 38 SUMITOMO HEAVY INDUSTRIES: COMPANY SNAPSHOT (2021)
12.1.13 PHILIPS HEALTHCARE
TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW
FIGURE 39 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022)
12.1.14 RAYSEARCH LABORATORIES
TABLE 87 RAYSEARCH LABORATORIES: COMPANY OVERVIEW
FIGURE 40 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2022)
12.1.15 PROTOM INTERNATIONAL, INC.
TABLE 88 PROTOM INTERNATIONAL, INC.: COMPANY OVERVIEW
12.1.16 OPTIVUS PROTON THERAPY, INC.
TABLE 89 OPTIVUS PROTON THERAPY, INC.: COMPANY OVERVIEW
12.1.17 TOSHIBA CORPORATION
TABLE 90 TOSHIBA CORPORATION: COMPANY OVERVIEW
FIGURE 41 TOSHIBA CORPORATION: COMPANY SNAPSHOT (2022)
12.1.18 VISION RT LTD.
TABLE 91 VISION RT LTD.: COMPANY OVERVIEW
12.1.19 ADVANCED ONCOTHERAPY PLC
TABLE 92 ADVANCED ONCOTHERAPY PLC: COMPANY OVERVIEW
12.1.20 MIM SOFTWARE INC.
TABLE 93 MIM SOFTWARE INC.: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, Recent Developments, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats might not be captured in case of unlisted companies.